Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome

Chun C. Chao, Edward N. Janoff, Shuxian Hu, +4

Cytokine

InflammationCytokineFatigue ManagementAutoimmune DiseaseImmune Regulation +8

Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells

Karl Egan, Darragh Crowley, Paul Smyth, +21

PLoS ONE

Platelet InteractionsCancer BiologyTumor BiologyOvarian CancerThrombosis +14

Atypical Chest Pain: Coronary, Aortic, and Pulmonary Vasculature Enhancement at Biphasic Single-Injection 64-Section CT Angiography

Thomas G. Vrachliotis, Kostaki G. Bis, Ahmad Haidary, +7

Radiology

Polyreactive antigen-binding B cells are the predominant cell type in the newborn B cell repertoire

Zhi Jian Chen, Carl J. Wheeler, Wei Shi, +4

European Journal of Immunology

ImmunohematologyImmunocytochemical TechniqueAdaptive Immune SystemHumoral ResponseImmunology +17

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC

Lauren MacDonagh, Michael Gallagher, Brendan Ffrench, +12

Oncotarget

Detection of adrenomedullin, a hypotensive peptide, in amniotic fluid and fetal membranes

Charles J. Macri, Alfredo Martı́nez, Terry W. Moody, +4

American Journal of Obstetrics and Gynecology

Adrenal GlandHypotensive PeptideAmniotic FluidMedicinePhysiology +8

Low MAD2 expression levels associate with reduced progression‐free survival in patients with high‐grade serous epithelial ovarian cancer

Fiona Furlong, Patricia Fitzpatrick, Sharon O’Toole, +14

The Journal of Pathology

OncologyMad2 IhcEpithelial Ovarian CancerMedicineGynecology +10

Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer

Lynda McEvoy, Sharon O’Toole, Cathy Spillane, +6

BMC Cancer

The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer

Charles J. d'Adhemar, Cathy Spillane, Michael Gallagher, +24

PLoS ONE

Epithelial Ovarian CancerImmunologyPathologyGynecologyAdverse Prognostic Factor +14

Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119)

Lawrence Berk, Brian Berkey, Tyvin A. Rich, +7

International Journal of Radiation Oncology*Biology*Physics

Rtog 0119Neuro-oncologyRpa Class 2OncologyRadiation Therapy +4